I am on 2.5mg branded Mounjaro. I have noticed that once I consume sweets I keep wanting them. I know this is kind of normal. But I have good suppression with normal foods, just not candy/sweets.
My blood sugar is being controlled well, which is primarily why I am on mounjaro. Anyone else had this happen to them? I do plan on cutting out sugar, but am not sure what if anything I should change now.
October 1, 2026
Coverage of the recent European Association for the Study of Diabetes (EASD) conference highlights how the next wave of metabolic and weight-loss therapies, specifically amylin-based medications, is set to transform the clinical landscape. While current GLP-1 receptor agonists have revolutionized obesity treatment, discontinuation rates remain fairly high, with roughly 40% of starting patients stopping their treatment within a year across all reasons. Amylin analogues act via distinct cellular receptors in the brain to curb appetite and slow gastric emptying, offering a complementary mechanism of action that achieves strong efficacy while causing severe nausea and vomiting at less than half the rate of GLP-1s.
Clinical trial data for three leading amylin candidates is encouraging. Novo Nordisk reported that CagriSema, a weekly co-formulation combining semaglutide with the amylin analogue cagrilintide, produced a 22.4% mean weight loss after one year in overweight or obese patients. Brain fMRI studies further demonstrated that CagriSema reduced food fixations, while additional trial data indicated improvements in liver and pancreatic fat as well as diabetic neuropathic pain. Novo Nordisk has submitted CagriSema to the FDA for regulatory approval.
Meanwhile, Eli Lilly presented results for EloraTZP, which combines its amylin analogue eloralintide with tirzepatide. In patients with obesity and Type 2 diabetes, EloraTZP delivered a 23% weight loss after nearly a year, compared to 14.8% for tirzepatide alone, alongside significant HbA1c reductions.
Additionally, Zealand Pharma shared phase trial data published in The Lancet for petrelintide, a standalone weekly amylin injection. Petrelintide achieved approximately 10% weight loss in non-diabetic participants while maintaining side-effect rates comparable to placebo, making it a promising candidate for standalone use.
Ultimately, medical experts emphasise that the arrival of amylin-based therapies will allow clinicians to better individualise care based on patient tolerance and weight-loss goals. Because amylins provide a gentler side-effect profile, they may serve as an attractive first-line option for patients seeking moderate weight loss without severe GI disruption or as high-efficacy combination therapies for those requiring greater metabolic management.
Hi all - I have been on Mounjaro for about 6 weeks so far and I have noticed a huge improvement in psoriasis. I usually only get it on my scalp (and a tiny bit elsewhere if stressed) but it is usually to the point that if I don't wash my hair with medicated shampoo then it drives me crazy after 3 or 4 days. This morning I couldn't remember when I last washed my hair (it would have been in the last week but don't remember the day)! Has anyone else had weird, seemingly unrelated health benefits like that?
October 5, 2026
A recent study published in Nature Metabolism by researchers at Virginia Tech’s Fralin Biomedical Research Institute investigates whether industrial food processing itself influences human health independently of basic nutrient content. While ultra-processed foods (UPFs) are widely linked to obesity and diabetes, nutrition science has debated whether these poor health outcomes stem strictly from poor macronutrient profiles, such as high sugar and low fiber, or from the processing methods. To test this, researchers designed a randomized crossover trial using meals that were nutritionally matched within 1 percent for calories, carbohydrates, fats, proteins, water, and salt, utilizing the international NOVA food classification scale to compare highly processed meals against minimally processed ones.
Participants consumed the matched meals inside a sealed metabolic chamber, allowing researchers to measure post-meal energy expenditure and blood metrics. The results revealed striking metabolic differences: the ultra-processed meals prompted a significantly higher insulin response, kept blood sugar elevated for longer, caused the body to expend more energy, and resulted in less carbohydrate burning for fuel. Furthermore, functional MRI (fMRI) brain scans showed that these metabolic shifts correlated directly with activity in the ventral striatum and nucleus accumbens - the brain regions responsible for motivation, learning, and reward.
These findings offer novel neurobiological evidence that industrial processing alters how both the body and brain handle food in ways that go far beyond standard macronutrient labels, potentially helping to explain why ultra-processed foods are so easily overconsumed. The researchers aim to build on these insights by examining larger and more diverse populations, longer observation windows, and different food pairings to pinpoint the exact commercial additives or manufacturing steps driving these distinct physiological responses.
I would love some feedback on the site claiming GLP-1s for around $100 a month for Trizepatide. For example, I’ve seen dollardadclub offering Zep for $200 a month. I have an existing Rx from my doc, so it should be pretty simple to fill through one of these online providers, correct?
Thank you for any guidance or insight you can provide!
Husband has been on GLP for over a year and has reached goal but now too expensive to continue Any suggestions ?
October 2, 2026
Eli Lilly and Novo Nordisk are betting big on amylin therapies as the next frontier in obesity care because amylin acts on an entirely separate biological pathway from GLP-1, offering a distinct metabolic lever to suppress appetite and slow digestion. This dual-pathway approach allows drugmakers to build combination regimens, such as Lilly’s eloralintide with tirzepatide or Novo’s CagriSema, that can push weight loss further, break through GLP-1 plateaus, and directly reduce neurological food noise without relying solely on higher GLP-1 doses. Crucially, standalone amylin drugs also unlock a massive alternative treatment pool for patients who fail to respond to, tolerate, or achieve adequate weight loss on standard GLP-1 medications alone.
This is in regards to solely anti-inflammatory benefits and not for weight loss.